Prostate cancer: to screen or not to screen

Area of Science:

• Oncology
• Preventive Medicine
• Medical Screening

Background:

• Prostate-specific antigen (PSA) testing is a widely discussed but controversial method for prostate cancer screening.
• Current evidence and guidelines for PSA screening remain unclear, leading to public and medical debate.

Purpose of the Study:

• To evaluate the efficacy of PSA screening for prostate cancer using the Wilson and Jungner screening criteria.
• To compare conflicting results from major randomized controlled trials on PSA screening and prostate cancer mortality.

Main Methods:

• Application of the Wilson and Jungner screening criteria to assess PSA testing suitability for population screening.
• Comparative analysis of the European Randomized trial of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colon and Ovarian (PLCO) cancer trial outcomes.

Main Results:

• The ERSPC trial indicated a 20% reduction in prostate cancer mortality with PSA screening (p=0.04).
• The PLCO trial found no significant impact of PSA screening on prostate cancer mortality.
• Discrepancies in trial outcomes are attributed to differences in methodology, study size, screening intervals, and demographic factors.

Conclusions:

• PSA screening demonstrates a moderate, at best, impact on prostate cancer mortality.
• PSA screening carries a substantial risk of over-diagnosis and over-treatment, leading to associated morbidity.
• Further data from ongoing studies like the ProtecT study and long-term ERSPC outcomes are needed; economic and quality of life evaluations are currently lacking.